Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06742281 · ClinicalTrials.gov registry record · Phase 2

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

A Phase 2 study of COVID-19, sponsored by CyanVac.

Active
Registry status
Phase 2
Development phase
432
Enrollment target
20
Study locations

NCT06742281 is a Phase 2 study of COVID-19 that is active but no longer recruiting, run by CyanVac. The registered enrollment target is 432 participants, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06742281, a Phase 2 study of COVID-19, is active but no longer recruiting, sponsored by CyanVac.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
432 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 434 healthy participants.

Conditions Studied

COVID-19

Interventions

  • BIOLOGICAL CVXGA (CVXGA50)
  • BIOLOGICAL COMIRNATY®

Study Locations (20)

California

  • Velocity Clinical Research, Chula Vista - Chula Vista
  • Velocity Clinical Research, San Diego - La Mesa
  • Imax Clinical Trials - La Palma
  • Artemis Institute for Clinical Research - Riverside
  • Clinical Innovations Inc. dba CITrials - Riverside
  • Avacare - Sacramento
  • Collaborative Neuroscience Research, LLC - Torrance

Florida

  • Velocity Clinical Research, Hallandale Beach - Hallandale
  • Homestead Associates in Research, Inc - Homestead
  • Biscayne Clinical Research - North Miami Beach
  • Headlands Research Orlando - Orlando
  • Best Choice Medical and Research Service - Pembroke Pines
  • Forcare Clinical Research - Tampa
  • Guardian Angel Research Center - Tampa

Georgia

  • Lifeline Primary Care/Avacare - Lilburn
  • Velocity Clinical Research, Savannah - Savannah
  • Clinical Research Atlanta - Stockbridge

Alabama

  • Pinnacle Research Group, LLC - Anniston

Arizona

  • Velocity Clinical Research, Phoenix - Phoenix

District of Columbia

  • Velocity Clinical Research, Washington DC - Washington D.C.

Trial Details

FieldValue
Enrollment Target 432 participants
Start Date 2024-12-05
Est. Completion 2027-06
Phase Phase 2

Sponsor

CyanVac

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06742281

The ClinicalTrials.gov registry entry for NCT06742281 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,212-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is CyanVac, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which CVXGA (CVXGA50) is the first listed.

NCT06742281 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06742281 about?

NCT06742281 is a clinical study titled "A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults". The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. Th...

What is the current status of trial NCT06742281?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2024-12-05. Estimated completion is 2027-06.

What conditions does trial NCT06742281 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT06742281?

The interventions under investigation include: CVXGA (CVXGA50) (BIOLOGICAL), COMIRNATY® (BIOLOGICAL).

Who is sponsoring clinical trial NCT06742281?

This trial is sponsored by CyanVac, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06742281 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.